Why has Revvity (RVTY) dropped 5.1% following its most recent earnings announcement?

Revvity Shares Decline Following Latest Earnings Report

Since Revvity’s most recent earnings announcement, the company’s stock price has dropped approximately 5.1%, trailing behind the performance of the S&P 500 during the same period.

Will the Downward Trend Persist?

To better understand what’s driving Revvity’s recent stock movement and to anticipate future performance, let’s review the highlights from the latest quarterly results and examine how the market and analysts have responded.

Fourth Quarter 2025 Financial Highlights

• Adjusted Earnings: Revvity posted adjusted earnings per share of $1.70 for Q4 2025, surpassing the Zacks Consensus Estimate of $1.63, marking a 4.3% beat and a 19.7% increase compared to the same quarter last year.
• GAAP Earnings: Earnings from continuing operations reached $0.87 per share, up from $0.78 in the prior-year period.

Revenue Performance

• Total revenue for the quarter was $772.1 million, reflecting a 5.9% year-over-year increase and 4% organic growth. This figure was nearly identical to analyst expectations.

Segment Breakdown

• Life Sciences: This division generated $382 million in revenue, remaining flat on an organic basis compared to the previous year. Adjusted operating income for the segment was $136 million, a 1.4% decrease year-over-year.
• Diagnostics: Revenue for this segment reached $390 million, up 10% from the prior year and 7% higher organically. Adjusted operating income was $91 million, unchanged from the previous year.

Margins and Expenses

• Selling, general, and administrative costs rose 3% to $251.7 million.
• Research and development spending increased 18.2% to $58.2 million.
• Adjusted operating income declined 3.6% to $229.4 million, with the adjusted operating margin narrowing by 60 basis points to 29.7%.

Financial Position

• At the end of Q4 2025, Revvity held $919.9 million in cash and equivalents, slightly down from $931.4 million at the end of the previous quarter.
• Net cash from operating activities totaled $582.9 million, compared to $628.3 million a year earlier.

2026 Outlook

• For 2026, Revvity anticipates adjusted earnings per share between $5.35 and $5.45.
• Revenue is projected to range from $2.96 billion to $2.99 billion.

Recent Estimate Revisions

Over the past month, analyst estimates for Revvity have been revised downward, with the consensus estimate decreasing by 7.66%.

VGM Score Overview

• Revvity currently holds a Growth Score of B, but its Momentum Score is a C, and its Value Score is also a C, placing it in the middle 20% for value among its peers.
• The overall VGM Score for the stock is B, which is useful for investors not focused on a single investment strategy.

Future Prospects

Analyst sentiment has generally turned more cautious, as reflected in the downward revisions to estimates. Revvity is assigned a Zacks Rank #3 (Hold), suggesting that the stock is expected to deliver returns in line with the market over the coming months.

Industry Comparison: HCA Healthcare

Within the Zacks Medical Services sector, HCA Healthcare (HCA) has seen its shares rise 8.5% over the past month. The company’s most recent quarterly report, covering the period ending December 2025, showed:

• Revenue of $19.51 billion, up 6.7% year-over-year.
• Earnings per share of $8.01, compared to $6.22 a year ago.
• For the current quarter, HCA is expected to report EPS of $7.18, an 11.3% increase from the prior year. The consensus estimate has edged up by 0.2% in the past month.
• HCA also holds a Zacks Rank #3 (Hold) and boasts a VGM Score of A.